Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)

The summary for the Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed): The purpose of this PAR is to support the development and evaluation of non-viral technologies to deliver genome editors to disease relevant somatic cells and tissues in vivo. The ultimate goal of these technologies is translation into clinical trials of genome editing to treat human disease.

Federal Grant Title:	Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-20-109
Type of Funding:	Grant
CFDA Numbers:	93.350
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 5th, 2022
Original Application Deadline:	January 5th, 2022
Posted Date:	February 6th, 2020
Creation Date:	February 6th, 2020
Archive Date:	February 10th, 2022
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	February 6th, 2020

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-20-109.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Single Source for the Continuation of the Data Management and Coordinating Center (DMCC) f...; • Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed); • Basket Clinical Trials of Drugs Targeting Shared Molecular Etiologies in Multiple Rare Dis...; • Miniaturization and Automation of Tissue Chip Systems (MATChS) (U43/U44 Clinical Trial Not...; • Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science ...; • Limited Competition: Revision Applications to Advance Evidence-Based Research Related to P...; • A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for...; • Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for E...
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...